The use of gadolinium-DTPA enhanced MR imaging (Gd-MR) in detecting and staging of large and small renal neoplasm was investigated in 61 patients with 66 renal cell carcinoma confirmed at surgery. The purpose of the study was also to evaluate the signal intensity of the lesions and to correlate the contrast-enhanced pattern to the pathological components and architecture of the surgical specimens. Forty-four tumors were larger than 3 cm and 22 lesions were smaller than 3 cm. Unenhanced MRI detected all large lesions (44/44) and 63% (14/22) of small lesions, while Gd-MRI detected all large and small neoplasms (100%). The overall staging accuracy was 79 and 87% for plain MRI and Gd-MRI, respectively, but both modalities led to an overstaging of the disease. Enhanced MRI was an excellent staging modality for the evaluation of tumor vascular extension and tumor spread to adjacent structures. The most frequent Gd-MRI pattern of small RCC was hyperintensity, while large lesions were mostly hypointense. The presence of fibrohyaline components seemed responsible for the hyperintense pattern. No specific contrast-enhanced MRI pattern was observed according to the tumor architecture (alveolar, tubular or papular) of noncystic lesions. On the contrary, cystic lesion appeared as an area of low signal intensity and the use of contrast media improved detection and characterization. The inhomogeneous signal intensity increased the detectability of the lesion.

Keywords:
Renal cell carcinoma, Gadolinium, Staging, Pathology
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.